- Home
- MERC vs ATOS Comparison
MERC vs ATOS Comparison
Compare MERC & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MERC | ATOS |
|---|---|---|
| Founded | 1968 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 100.8M |
| IPO Year | 1987 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MERC | ATOS |
|---|---|---|
| Price | $2.07 | $0.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $3.00 | ★ $6.33 |
| AVG Volume (30 Days) | 737.4K | ★ 1.2M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 7.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,906,971,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.48 | $0.55 |
| 52 Week High | $8.28 | $1.29 |
Technical Indicators
Market Signals| Indicator | MERC | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 35.76 |
| Support Level | $1.98 | $0.70 |
| Resistance Level | $2.15 | $0.75 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 51.82 | 3.13 |
Price Performance
Historical ComparisonAbout MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.